Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35220403

about

Clinical implications of the molecular genetics of chronic lymphocytic leukemia The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.The genomic landscape of chronic lymphocytic leukemia: clinical implications.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.Genomic approaches to chronic lymphocytic leukemia.Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34 Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling.Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.Whole genome profiling and other high throughput technologies in lymphoid neoplasms--current contributions and future hopes.Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications.Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.The molecular pathogenesis of chronic lymphocytic leukaemia.SNP Array in Hematopoietic Neoplasms: A Review.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia.Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.

P2860

Q26830955-36D65AA0-19F1-4B1C-A3AE-D7513CBF70A1 Q27024411-635E03D4-C58E-40F5-90F3-B55729A3D7A1 Q28394721-586A5E6F-7C0C-4F3F-9E09-2CBB934F7132 Q33409459-4AD69704-8DA8-46A6-89E8-CFBA75358866 Q33567169-4BBF8972-A5E6-4B39-9F87-231EA7816B89 Q33744997-E4F8CF18-5AC4-4C85-B073-83FE5462C503 Q33818637-F60A5328-2923-4DC6-B4C2-EA468A225144 Q34710882-9331A34B-04F7-4408-83E0-1AD0C3E27A7F Q35860550-E9290C03-3720-40DC-92CA-32534975F114 Q35984259-99787175-14A1-43E7-9A26-77520EB81AE3 Q36301081-7FF880A8-328E-4D97-AAFC-1ED038F9DF8F Q36421804-2B62689C-A64F-4A76-B7E6-FC8569B87293 Q36520447-5422B99F-77C3-424E-B8F3-004B95D4F662 Q36591941-24CFEE31-42A3-4E60-85A3-846A0EF6067B Q36651908-4FCC2FF7-3757-41C3-B6B7-B69BD8AC324E Q36737322-703826D3-8CB2-4473-A431-B03361ECF784 Q36790673-44E2C0F0-00D6-446F-8815-1C482E808922 Q36799831-5841608D-E0A8-406D-A124-6475C86A4DE8 Q36842838-9759E91B-FA5A-456D-84CF-D7D207CB91E2 Q36906625-7498B4C7-9734-4610-84C7-6898AC01AEED Q37037294-92568D88-A4FD-4BDF-847B-0CCD0224B0BD Q37225819-6E9AA0A0-17FF-49F4-BE2A-92A6B1CE11A7 Q37410709-04E27944-35C3-498D-9F6B-0BEEAD642912 Q37528942-EBF2CD0F-60B9-4F54-B423-B8995D152C28 Q37552043-22A341F2-4508-4385-9967-055D7E69B0C0 Q37618663-A3A6451B-DC77-4EEE-88D6-33F8F339A20F Q37697850-7EA1D972-C483-4024-962F-09EE4C99E52C Q38071077-3CEF97FC-FD3D-4472-B898-7F0C78ADA43D Q38259446-0D946737-6334-4781-9191-4A3F9BC55E5B Q38286344-04A039E0-BDF2-440C-80F2-0512A68104C3 Q38612097-E20AE25A-1903-4C10-BB7D-63DF593C702E Q38744632-9C02F9E5-B899-452A-B597-5606A80F0FF5 Q38748645-D72C3B02-F185-4BA9-B7BE-BBEDDEC7322B Q38947537-274838FD-4B4B-49E7-BDAA-8E50B1B09CE4 Q38970612-89B4AAC0-B173-4CF8-A931-31F7332D8AB7 Q39085428-804A5C98-228C-4F07-B484-70CB76FBBD39 Q41280348-A4F6D4D3-73B0-4207-89F8-DCA0E286C1DC Q41310328-A3A72549-52E8-4B29-9FDA-0765C6FE322E Q41848521-E1F52AB6-48EA-4FF9-991A-3761A1BF9334 Q42537560-5EED8D8D-897B-4C94-9AA4-4BF157BE7F2B

P2860

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q35220403

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@ast

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@en

type

label

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@ast

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@en

prefLabel

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@ast

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@en

P1433

Q35220403-CBAD63EB-9604-4BE7-9E91-DF8627AD86B9

P1476

Q35220403-99706771-83B9-495F-A08C-654AA391E21A

P2093

Q35220403-2798B375-AF05-4155-843A-E5C78BE21BB9

Q35220403-2E54EBB2-8A5E-45DA-8F25-2A7F07F5291E

Q35220403-4C87F770-9777-42EF-9202-747F2D6A987B

Q35220403-87AACBE3-16F6-4295-AF6C-B6CDC2909338

Q35220403-8E8A38CA-F160-48FF-A903-027A96D5ECE1

Q35220403-9D0516DD-F7AC-4145-BE14-0D9414590712

Q35220403-A125D04E-D425-4B8E-99FF-BDF40FB5E885

Q35220403-AC7A8E28-FFCE-4729-BB83-395710EF7734

Q35220403-AF2943ED-DA29-4DB3-A830-C070F4DD28AF

Q35220403-B0F1AFC6-E54E-4BF7-85A4-569D219F5883

P2860

Q35220403-00216B01-9AF0-4DAC-9FD2-D607AFC26BCC

Q35220403-03AA9B42-D790-45F0-ADF4-CBF74E4C0FEA

Q35220403-045165D4-4779-4D88-8DDE-514E6FC37A65

Q35220403-06EA1452-D8DD-4D44-A239-72C3EBB9B3F5

Q35220403-0E669B2F-DFBF-46E1-800B-2F9AB133D21F

Q35220403-10695351-74CA-4935-A92F-FE08F02400AC

Q35220403-10C77C3F-1DAE-4DA7-86A8-A88DEDE96136

Q35220403-147C1ADB-1B80-4E1A-9C8D-2E4B18F84B71

Q35220403-2921357D-6929-49F1-9216-89999D3E8462

Q35220403-4250FAF0-356A-4F82-BAFF-8FA745E210C3

P304

Q35220403-B0453DAB-5BEE-44F7-99F3-C57F3E104D82

P31

Q35220403-F2862A96-0A42-4C5E-9B82-E57A7387F6E0

P356

Q35220403-59F43384-6A47-495E-AF4E-2B3DE81E9610

P407

Q35220403-CAA0E2CF-5547-4874-9576-404461AFE3F5

P433

Q35220403-1BB70BB9-94A4-4A79-98AC-45CC2B8EC400

P478

Q35220403-87993531-038E-42B1-995F-0A729DAF8EB6

P577

Q35220403-86203D8E-60F6-4D08-8C35-90669E38EE10

P5875

Q35220403-F61B6F8A-00A4-4AE3-8AA3-2168E1C9A5DA

P698

Q35220403-61FF4130-3AE1-480D-A81B-CBE656978A33

P921

Q35220403-1AB240CA-4E37-4F77-8105-7BB56FFDEB39

Q35220403-9312A7AB-C0CB-4B98-B7E5-B1C19C54C470

P932

Q35220403-9DBA45C2-F008-4ADF-9CF6-6CF49D11511C

P356

BLOOD-2010-12-327858

P1433

P1476

Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.

@en

P2093

Cheng Li

http://www.w3.org/2001/XMLSchema#string

Edward Peres

http://www.w3.org/2001/XMLSchema#string

Jinghui Li

http://www.w3.org/2001/XMLSchema#string

Kerby Shedden

http://www.w3.org/2001/XMLSchema#string

Lisa Kujawski

http://www.w3.org/2001/XMLSchema#string

Mark Kaminski

http://www.w3.org/2001/XMLSchema#string

Moshe Talpaz

http://www.w3.org/2001/XMLSchema#string

Peter Ouillette

http://www.w3.org/2001/XMLSchema#string

Roxane Collins

http://www.w3.org/2001/XMLSchema#string

Sajid Shakhan

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

Genomic aberrations and survival in chronic lymphocytic leukemia

Chronic lymphocytic leukemia

The DNA damage response: ten years after

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data.

P304

3051-3061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-12-327858

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51527299

http://www.w3.org/2001/XMLSchema#string

P698

21795749

http://www.w3.org/2001/XMLSchema#string

P921

P932

3175782

http://www.w3.org/2001/XMLSchema#string